TNFRSF1A and CDK6 |
TNF receptor superfamily member 1A |
cyclin dependent kinase 6 |
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- TNFR1-mediated ceramide production
- TNFs bind their physiological receptors
- Interleukin-10 signaling
- TNF signaling
|
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Cyclin D associated events in G1
- Regulation of RUNX1 Expression and Activity
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
|
- 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
|
- Alvocidib
- (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol
- 3,7,3',4'-TETRAHYDROXYFLAVONE
- Palbociclib
- Ribociclib
- Abemaciclib
|
- Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
|
|
CHUK and CSF2RA |
component of inhibitor of nuclear factor kappa B kinase complex |
colony stimulating factor 2 receptor subunit alpha |
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- AKT phosphorylates targets in the cytosol
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- Constitutive Signaling by AKT1 E17K in Cancer
- NIK - noncanonical NF-kB signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
- Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
- Interleukin receptor SHC signaling
|
- Aminosalicylic Acid
- Mesalazine
- Sulfasalazine
- Acetylcysteine
|
- Sargramostim
- KB002
- recombinant human GM-CSF
|
|
|
LRP2 and CLU |
LDL receptor related protein 2 |
clusterin |
- Vitamin D (calciferol) metabolism
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- Retinoid metabolism and transport
|
- Platelet degranulation
- Terminal pathway of complement
- Antimicrobial peptides
- Regulation of Complement cascade
|
- Urokinase
- Insulin Human
- Insulin Pork
- Gentamicin
|
|
- Donnai-Barrow syndrome; Faciooculoacousticorenal syndrome
|
|
LCK and CSF2RB |
LCK proto-oncogene, Src family tyrosine kinase |
colony stimulating factor 2 receptor subunit beta |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Nef Mediated CD4 Down-regulation
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- CTLA4 inhibitory signaling
- PD-1 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Interleukin-2 signaling
|
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
- Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
- Interleukin receptor SHC signaling
|
- Dasatinib
- {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- (4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
- Nintedanib
|
- Sargramostim
- NPI 32101
- Resatorvid
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|
|
HSPB1 and RBPJ |
heat shock protein family B (small) member 1 |
recombination signal binding protein for immunoglobulin kappa J region |
- VEGFA-VEGFR2 Pathway
- AUF1 (hnRNP D0) binds and destabilizes mRNA
- MAPK6/MAPK4 signaling
- Extra-nuclear estrogen signaling
|
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 intracellular domain regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Notch-HLH transcription pathway
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
- Apatorsen
- Phenethyl Isothiocyanate
|
|
- Distal hereditary motor neuropathies (dHMN)
|
|
TNFRSF1A and IKBKB |
TNF receptor superfamily member 1A |
inhibitor of nuclear factor kappa B kinase subunit beta |
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- TNFR1-mediated ceramide production
- TNFs bind their physiological receptors
- Interleukin-10 signaling
- TNF signaling
|
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
- 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
|
- Mesalazine
- Sulfasalazine
- Acetylsalicylic acid
- Auranofin
- Arsenic trioxide
- MLN0415
- Acetylcysteine
|
- Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
|
|
LRP2 and LCN2 |
LDL receptor related protein 2 |
lipocalin 2 |
- Vitamin D (calciferol) metabolism
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- Retinoid metabolism and transport
|
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Metal sequestration by antimicrobial proteins
- Iron uptake and transport
- Iron uptake and transport
|
- Urokinase
- Insulin Human
- Insulin Pork
- Gentamicin
|
- Methyl Nonanoate (Ester)
- 2,3-Dihydroxy-Benzoic Acid
- Carboxymycobactin S
- 2,3,-Dihydroxybenzoylserine
- Carboxymycobactin T
- Trencam-3,2-Hopo
|
- Donnai-Barrow syndrome; Faciooculoacousticorenal syndrome
|
|
LRP2 and RAC1 |
LDL receptor related protein 2 |
Rac family small GTPase 1 |
- Vitamin D (calciferol) metabolism
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- Retinoid metabolism and transport
|
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Nef and signal transduction
- NRAGE signals death through JNK
- Rho GTPase cycle
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- FCERI mediated MAPK activation
- DSCAM interactions
- CD28 dependent Vav1 pathway
- EPHB-mediated forward signaling
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- Sema3A PAK dependent Axon repulsion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- PCP/CE pathway
- Sema4D mediated inhibition of cell attachment and migration
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Activation of RAC1
- Inactivation of CDC42 and RAC1
- VEGFA-VEGFR2 Pathway
- Signal transduction by L1
- VEGFR2 mediated vascular permeability
- RHO GTPases activate PKNs
- RHO GTPases activate CIT
- RHO GTPases activate CIT
- RHO GTPases activate KTN1
- RHO GTPases activate IQGAPs
- RHO GTPases activate PAKs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate Formins
- RHO GTPases Activate Formins
- RHO GTPases Activate NADPH Oxidases
- MAPK6/MAPK4 signaling
- Neutrophil degranulation
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAP1 and RAC1
- NTRK2 activates RAC1
- Activated NTRK2 signals through CDK5
- Activation of RAC1 downstream of NMDARs
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- WNT5:FZD7-mediated leishmania damping
- Factors involved in megakaryocyte development and platelet production
|
- Urokinase
- Insulin Human
- Insulin Pork
- Gentamicin
|
- Dextromethorphan
- Azathioprine
- Guanosine-5'-Diphosphate
|
- Donnai-Barrow syndrome; Faciooculoacousticorenal syndrome
|
|
SFTPC and CXCL9 |
surfactant protein C |
C-X-C motif chemokine ligand 9 |
- Surfactant metabolism
- Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS)
- Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
- Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
|
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
|
|
|
- Pulmonary surfactant metabolism dysfunction (SMDP)
|
|
HTRA1 and NOS3 |
HtrA serine peptidase 1 |
nitric oxide synthase 3 |
- Degradation of the extracellular matrix
|
- ROS and RNS production in phagocytes
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- eNOS activation
- NOSTRIN mediated eNOS trafficking
- NOSIP mediated eNOS trafficking
- Nitric oxide stimulates guanylate cyclase
- VEGFR2 mediated vascular permeability
- Extra-nuclear estrogen signaling
|
|
- L-Arginine
- L-Citrulline
- Sapropterin
- Miconazole
- N,N-dimethylarginine
- L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
- L-2-Amino-4-(Guanidinooxy)Butyric Acid
- 3-Bromo-7-Nitroindazole
- N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine
- N-(3-(Aminomethyl)Benzyl)Acetamidine
- 1,2,4-Triazole-Carboxamidine
- L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
- S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 7-Nitroindazole
- S-Ethylisothiourea
- 2-Aminothiazoline
- Se-Ethyl-Isoselenourea
- 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
- N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
- Cacodylic acid
- 7-Nitroindazole-2-Carboxamidine
- 6-Nitroindazole
- N-Omega-Hydroxy-L-Arginine
- N5-Iminoethyl-L-Ornithine
- 5,6-Cyclic-Tetrahydropteridine
- S-Ethyl-N-Phenyl-Isothiourea
- S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 6S-5,6,7,8-Tetrahydrobiopterin
- S-(Dimethylarsenic)Cysteine
- L-Homoarginine
- S-Isopropyl-Isothiourea
- Nitroarginine
- 5-Nitroindazole
- N-(Chlorophenyl)-N'-Hydroxyguanidine
- Apremilast
- (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine
- 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
|
- Macular degeneration, including: Age-related macular degeneration (ARMD); Patterned dystrophy of retinal pigment epithelium (PDREP); Retinal macular dystrophy 2 (MCDR2); X-linked atrophic macular degeneration (MDXLA)
|
|
NTRK3 and HEY1 |
neurotrophic receptor tyrosine kinase 3 |
hes related family bHLH transcription factor with YRPW motif 1 |
- Receptor-type tyrosine-protein phosphatases
- NTF3 activates NTRK3 signaling
- NTF3 activates NTRK3 signaling
- Signaling by NTRK3 (TRKC)
- Activated NTRK3 signals through PLCG1
- Activated NTRK3 signals through PLCG1
- Activated NTRK3 signals through RAS
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- NTRK3 as a dependence receptor
|
- NOTCH1 Intracellular Domain Regulates Transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- RUNX2 regulates osteoblast differentiation
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
|
|
|
|
LTBP4 and RAC1 |
latent transforming growth factor beta binding protein 4 |
Rac family small GTPase 1 |
- Molecules associated with elastic fibres
|
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Nef and signal transduction
- NRAGE signals death through JNK
- Rho GTPase cycle
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- FCERI mediated MAPK activation
- DSCAM interactions
- CD28 dependent Vav1 pathway
- EPHB-mediated forward signaling
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- Sema3A PAK dependent Axon repulsion
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- PCP/CE pathway
- Sema4D mediated inhibition of cell attachment and migration
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Activation of RAC1
- Inactivation of CDC42 and RAC1
- VEGFA-VEGFR2 Pathway
- Signal transduction by L1
- VEGFR2 mediated vascular permeability
- RHO GTPases activate PKNs
- RHO GTPases activate CIT
- RHO GTPases activate CIT
- RHO GTPases activate KTN1
- RHO GTPases activate IQGAPs
- RHO GTPases activate PAKs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate Formins
- RHO GTPases Activate Formins
- RHO GTPases Activate NADPH Oxidases
- MAPK6/MAPK4 signaling
- Neutrophil degranulation
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAP1 and RAC1
- NTRK2 activates RAC1
- Activated NTRK2 signals through CDK5
- Activation of RAC1 downstream of NMDARs
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- WNT5:FZD7-mediated leishmania damping
- Factors involved in megakaryocyte development and platelet production
|
|
- Dextromethorphan
- Azathioprine
- Guanosine-5'-Diphosphate
|
- Cutis laxa with severe pulmonary, gastrointestinal, and urinary abnormalities; Urban-Rifkin-Davis syndrome
|
|
TNFRSF1A and SRC |
TNF receptor superfamily member 1A |
SRC proto-oncogene, non-receptor tyrosine kinase |
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- TNFR1-mediated ceramide production
- TNFs bind their physiological receptors
- Interleukin-10 signaling
- TNF signaling
|
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- Signaling downstream of RAS mutants
|
- 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
|
- Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
|
|
TNFRSF1A and TRAF3 |
TNF receptor superfamily member 1A |
TNF receptor associated factor 3 |
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- TNFR1-mediated ceramide production
- TNFs bind their physiological receptors
- Interleukin-10 signaling
- TNF signaling
|
- TRAF3 deficiency - HSE
- TNFR2 non-canonical NF-kB pathway
- TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
- Ovarian tumor domain proteases
- TICAM1-dependent activation of IRF3/IRF7
- TRAF3-dependent IRF activation pathway
- Negative regulators of DDX58/IFIH1 signaling
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
- 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
|
|
- Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
|
|
TNFRSF1B and TRAF3 |
TNF receptor superfamily member 1B |
TNF receptor associated factor 3 |
- TNFR2 non-canonical NF-kB pathway
- TNFs bind their physiological receptors
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
|
- TRAF3 deficiency - HSE
- TNFR2 non-canonical NF-kB pathway
- TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
- Ovarian tumor domain proteases
- TICAM1-dependent activation of IRF3/IRF7
- TRAF3-dependent IRF activation pathway
- Negative regulators of DDX58/IFIH1 signaling
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
|
|
- Graft-versus-host disease
|
|
MAPK14 and NFATC1 |
mitogen-activated protein kinase 14 |
nuclear factor of activated T cells 1 |
- NOD1/2 Signaling Pathway
- p38MAPK events
- p38MAPK events
- ERK/MAPK targets
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Oxidative Stress Induced Senescence
- DSCAM interactions
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- VEGFA-VEGFR2 Pathway
- activated TAK1 mediates p38 MAPK activation
- Activation of the AP-1 family of transcription factors
- KSRP (KHSRP) binds and destabilizes mRNA
- Myogenesis
- Myogenesis
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- CD163 mediating an anti-inflammatory response
|
- Calcineurin activates NFAT
- Calcineurin activates NFAT
- FCERI mediated Ca+2 mobilization
- Ca2+ pathway
- CLEC7A (Dectin-1) induces NFAT activation
|
- Dasatinib
- 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
- N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- KC706
- Talmapimod
- VX-702
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- Neflamapimod
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
- PH-797804
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
|
|
|
|
MAPK14 and ROBO1 |
mitogen-activated protein kinase 14 |
roundabout guidance receptor 1 |
- NOD1/2 Signaling Pathway
- p38MAPK events
- p38MAPK events
- ERK/MAPK targets
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Oxidative Stress Induced Senescence
- DSCAM interactions
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- VEGFA-VEGFR2 Pathway
- activated TAK1 mediates p38 MAPK activation
- Activation of the AP-1 family of transcription factors
- KSRP (KHSRP) binds and destabilizes mRNA
- Myogenesis
- Myogenesis
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- CD163 mediating an anti-inflammatory response
|
- Netrin-1 signaling
- Signaling by ROBO receptors
- Signaling by ROBO receptors
- Activation of RAC1
- Regulation of commissural axon pathfinding by SLIT and ROBO
- Regulation of commissural axon pathfinding by SLIT and ROBO
- Inactivation of CDC42 and RAC1
- Role of ABL in ROBO-SLIT signaling
- Role of ABL in ROBO-SLIT signaling
- SLIT2:ROBO1 increases RHOA activity
- Regulation of cortical dendrite branching
- Regulation of expression of SLITs and ROBOs
- Regulation of expression of SLITs and ROBOs
|
- Dasatinib
- 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
- N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- KC706
- Talmapimod
- VX-702
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- Neflamapimod
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
- PH-797804
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
|
|
|
|
CSF2RA and RPSA |
colony stimulating factor 2 receptor subunit alpha |
ribosomal protein SA |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
- Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
- Interleukin receptor SHC signaling
|
- L13a-mediated translational silencing of Ceruloplasmin expression
- Peptide chain elongation
- SRP-dependent cotranslational protein targeting to membrane
- SRP-dependent cotranslational protein targeting to membrane
- Viral mRNA Translation
- Selenocysteine synthesis
- Major pathway of rRNA processing in the nucleolus and cytosol
- Translation initiation complex formation
- Formation of a pool of free 40S subunits
- Formation of the ternary complex, and subsequently, the 43S complex
- Ribosomal scanning and start codon recognition
- GTP hydrolysis and joining of the 60S ribosomal subunit
- Eukaryotic Translation Termination
- Regulation of expression of SLITs and ROBOs
- Response of EIF2AK4 (GCN2) to amino acid deficiency
- Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
|
- Sargramostim
- KB002
- recombinant human GM-CSF
|
|
|
|
CSF2RA and IKBKB |
colony stimulating factor 2 receptor subunit alpha |
inhibitor of nuclear factor kappa B kinase subunit beta |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
- Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
- Interleukin receptor SHC signaling
|
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
- Sargramostim
- KB002
- recombinant human GM-CSF
|
- Mesalazine
- Sulfasalazine
- Acetylsalicylic acid
- Auranofin
- Arsenic trioxide
- MLN0415
- Acetylcysteine
|
|
|
CSF2RB and IKBKB |
colony stimulating factor 2 receptor subunit beta |
inhibitor of nuclear factor kappa B kinase subunit beta |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
- Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
- Interleukin receptor SHC signaling
|
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
- Sargramostim
- NPI 32101
- Resatorvid
|
- Mesalazine
- Sulfasalazine
- Acetylsalicylic acid
- Auranofin
- Arsenic trioxide
- MLN0415
- Acetylcysteine
|
|
|